An interventional study of Evalyn® Brush and Copan Floqswab in Cervical Cancer, Hpv and Human Papilloma Virus, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to female participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Thomas Jefferson University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 256th largest by planned enrollment of the 678 interventional ones that give a count, is one of 47 that started in 2025, is one of 246 with no phase, reaches primary completion later than 51 of the 217 other live ones, and was the 807th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 30–65 · Women only · Healthy volunteers
Florida A&M University · Sites in United States
Ages 21–65 · Women only · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
Mark Bernard · Sites in United States
Ages 18–99
University of Florida · Sites in United States
Ages 25+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 25 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
834 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 242 · Phase 2 240 · Phase 3 45 · Phase 4 9
First in 1992; this study’s year is marked. 47 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 71 across the 678 interventional studies, 138 across the 124 observational. Of the 570 that completed or were terminated, 193 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 834 have an industry lead sponsor. The 10 most frequent:
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
Thomas Jefferson University has 3 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
84 of the studies in Uterine Cervical Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT02285192Memorial Sloan Kettering Cancer CenterPositron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | 2026-11 |
| NCT05758688Abramson Cancer Center at Penn MedicinePROton Therapy for Post Surgical Treatment of GYNecologic Cancer | 2026-11 |
| NCT07574190University of South DakotaA Mobile Web App Intervention to Promote Cervical Cancer Screening | 2026-11 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
Add all 84 to your calendar (.ics) → With an account.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase I: Validating self-collection kit by comparing their results with clinical Pap smear results in a cohort of 20 patients.
Phase II: Evaluate the feasibility and acceptability of the CHW4CervicalHealth: Use of a self-collection kit to improve cervical health screening intervention aimed to promote HPV self-collection uptake among screening-eligible and under-screened ethnic minority women in the community.
The self-collection kits will be collected at the clinic (Phase I) or at the end of the workshop (Phase II). A chain-of-custody form for each kit will be associated with the specimen and the clinic nurse will label and prepare to transport them via courier to the Jefferson NJ Molecular Virology lab, Cherry Hill, NJ; Richard Sunday, Lab Supervisor, will process according to Roche, the self-collected vaginal specimens suspended in PreservCyt® may be stored at 2-30°C (35.6- 86°F) for up to 1 month after the date of collection.
Phase I: In person accrual, enrollment and study implementation will take 15-30 minutes.
-Clinic staff will collect self-collection kit at appointment.
Phase II: Workshops will take about 30 minutes to complete and another 30 minutes to complete survey and self-collection kit use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase I:
Phase II:
This intervention targets under-screened minority individuals who must meet all the following inclusion criteria to be eligible to participate in the study:
Exclusion Criteria:
Phase I:
Phase II:
An individual who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be provided the Evalyn Brush self-sample kit at their scheduled Pap smear; a self-collected HPV test will also be collected as part of validation purposes for the study. Results will be shared from both their regularly scheduled appointment and the HPV self sample kit.
Device: Evalyn® Brush
Participants will be assigned to use the Evalyn Brush device to evaluate feasibility and acceptability of use. Trained bilingual community health workers (CHWs) will provide culturally-tailored community workshops about cervical health and cervical cancer prevention, distribution and collection of HPV self-collection, and follow-up from results when appropriate.
Device: Evalyn® Brush · Behavioral: CHW4CervicalHealth
Participants will be assigned to use the Copan FLOQSwab device to evaluate feasibility and acceptability of use. Trained bilingual community health workers (CHWs) will provide culturally-tailored community workshops about cervical health and cervical cancer prevention, distribution and collection of HPV self-collection, and follow-up from results when appropriate.
Device: Copan Floqswab · Behavioral: CHW4CervicalHealth
Participants use Evalyn® Brush device to collect a cervical sample for HPV testing.
Also known as: Rovers® Self-Sampling Device, simply Evalyn, Viba-Brush®
Participants use the Copan Floqswab device to collect a cervical sample for HPV testing.
Also known as: 4N6FLOQSwabs® Genetics, eSwab®, hDNA Free FLOQSwabs®, flocked swabs, nylon-tipped swabs
The CHW4CervicalHealth intervention is a community health care worker (CHW)-led education and support program designed to promote HPV self-collection among underserved women. Trained bilingual CHWs provide culturally-tailored community workshops about cervical health and cervical cancer prevention, distribution and collection of HPV self-collection, and follow-up from results when appropriate.
Diagnostic Concordance of Self-Collected vs. Clinically collected sample (Phase I)
Concordance rate between self-collection kit results and clinical Pap smear findings (measured as agreement in detection of HPV and/or abnormal cytology). Agreement between the two methods will be evaluated using Cohen's kappa statistic, with values interpreted based on standard benchmarks for strength of agreement. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) will be calculated to determine the accuracy of self-collection kits relative to the clinician-collected gold standard.
Time frame: at the visit (approximately 30 minutes) and analysis completed within 2 weeks
Feasibility of HPV Self-Collection: Completion of Self-Collection Kit
Feasibility will be assessed as the number of participants who proceed with HPV self-collection using the study kit out of the total number of participants enrolled in the study.
Time frame: Within 12 months
Change in Participants' HPV-related knowledge and perceived comfort with self-collection
Paired sample t-tests will analyze changes in knowledge scores from baseline to post-intervention. Statistical analysis will be conducted using SPSS 25, with significance set at p \< .05.
Time frame: From Baseline to Post-Intervention (approximately 18 months)
Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 13 months is below that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.